Glycemic control should be assessed with HbA1c every 3 months
As a phase 2 dose-ranging study, this trial was not designed to provide the definitive efficacy evidence required for regulatory submission
The medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2
Fernndez-Milln E, Martn MA, Goya L, Lizrraga-Mollinedo E, Escriv F, Ramos S, lvarez C (2016) Glucagon-like peptide-1 improves beta-cell antioxidant capacity via extracellular regulated kinases pathway and Nrf2 translocation
This combination may be particularly effective for women with severe insulin resistance who need maximum metabolic support
Because the protocol is built alongside the Precision Peptide Genetic Test, a dosing plan can be weighed against your own metabolic pathway biology instead of a generalized assumption applied to everyone